A Phase 3 Randomized, Double-blind, Multi-
center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma – Bristol-Myers Squibb CA209-274, NCT02632409
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
MORE DETAILS ON THIS TRIAL:
16052 / NCT02632409 / Open 11-30-2016